Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Accelerator mass spectrometry detection of beryllium ions in the antigen processing and presentation pathway.

Tooker BC, Brindley SM, Chiarappa-Zucca ML, Turteltaub KW, Newman LS.

J Immunotoxicol. 2015 Apr-Jun;12(2):181-7. doi: 10.3109/1547691X.2014.917748. Epub 2014 Jun 16.

2.

Self-presentation of beryllium by BAL CD4+ T cells: T cell-T cell interactions and their potential role in chronic beryllium disease.

Fontenot AP, Edwards DM, Chou YK, Mack DG, LaTocha D, Vandenbark AA, Burrows GG.

Eur J Immunol. 2006 Apr;36(4):930-9.

3.

Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.

Fontenot AP, Torres M, Marshall WH, Newman LS, Kotzin BL.

Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12717-22.

4.

Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease.

Mack DG, Falta MT, McKee AS, Martin AK, Simonian PL, Crawford F, Gordon T, Mercer RR, Hoover MD, Marrack P, Kappler JW, Tuder RM, Fontenot AP.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8553-8. doi: 10.1073/pnas.1408048111. Epub 2014 May 27.

5.

Role of high-affinity HLA-DP specific CLIP-derived peptides in beryllium binding to the HLA-DPGlu69 berylliosis-associated molecules and presentation to beryllium-sensitized T cells.

Amicosante M, Berretta F, Dweik R, Saltini C.

Immunology. 2009 Sep;128(1 Suppl):e462-70. doi: 10.1111/j.1365-2567.2008.03000.x. Epub 2008 Dec 23.

6.

Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP.

Sawyer RT, Parsons CE, Fontenot AP, Maier LA, Gillespie MM, Gottschall EB, Silveira L, Newman LS.

Am J Respir Cell Mol Biol. 2004 Jul;31(1):122-30. Epub 2004 Feb 19.

PMID:
14975942
7.

Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis.

Chou YK, Edwards DM, Weinberg AD, Vandenbark AA, Kotzin BL, Fontenot AP, Burrows GG.

J Immunol. 2005 Apr 1;174(7):4316-24.

8.

Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease.

Falta MT, Pinilla C, Mack DG, Tinega AN, Crawford F, Giulianotti M, Santos R, Clayton GM, Wang Y, Zhang X, Maier LA, Marrack P, Kappler JW, Fontenot AP.

J Exp Med. 2013 Jul 1;210(7):1403-18.

9.

Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease.

Tinkle SS, Kittle LA, Newman LS.

J Immunol. 1999 Sep 1;163(5):2747-53.

10.

Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease.

Sawyer RT, Day BJ, Fadok VA, Chiarappa-Zucca M, Maier LA, Fontenot AP, Silveira L, Newman LS.

Am J Respir Cell Mol Biol. 2004 Oct;31(4):470-7. Epub 2004 Jul 15.

PMID:
15256386
11.

Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP.

Fontenot AP, Newman LS, Kotzin BL.

Clin Immunol. 2001 Jul;100(1):4-14. Review. No abstract available.

PMID:
11414740
12.

Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain.

Bill JR, Mack DG, Falta MT, Maier LA, Sullivan AK, Joslin FG, Martin AK, Freed BM, Kotzin BL, Fontenot AP.

J Immunol. 2005 Nov 15;175(10):7029-37.

13.

CpG promoter methylation status is not a prognostic indicator of gene expression in beryllium challenge.

Tooker BC, Ozawa K, Newman LS.

J Immunotoxicol. 2016 May;13(3):417-27. doi: 10.3109/1547691X.2015.1115447. Epub 2015 Dec 16.

14.

Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells.

Fontenot AP, Keizer TS, McCleskey M, Mack DG, Meza-Romero R, Huan J, Edwards DM, Chou YK, Vandenbark AA, Scott B, Burrows GG.

J Immunol. 2006 Sep 15;177(6):3874-83.

15.

HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease.

Lombardi G, Germain C, Uren J, Fiorillo MT, du Bois RM, Jones-Williams W, Saltini C, Sorrentino R, Lechler R.

J Immunol. 2001 Mar 1;166(5):3549-55.

16.

HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells.

Amicosante M, Berretta F, Franchi A, Rogliani P, Dotti C, Losi M, Dweik R, Saltini C.

Eur Respir J. 2002 Nov;20(5):1174-8.

17.

T cell recognition in chronic beryllium disease.

Amicosante M, Fontenot AP.

Clin Immunol. 2006 Nov;121(2):134-43. Epub 2006 May 12. Review.

PMID:
16697706
18.

Recent advances in understanding the biomolecular basis of chronic beryllium disease: a review.

McCleskey TM, Buchner V, Field RW, Scott BL.

Rev Environ Health. 2009 Apr-Jun;24(2):75-115. Review.

PMID:
19658317
19.
20.

Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove.

Silveira LJ, McCanlies EC, Fingerlin TE, Van Dyke MV, Mroz MM, Strand M, Fontenot AP, Bowerman N, Dabelea DM, Schuler CR, Weston A, Maier LA.

J Immunol. 2012 Oct 15;189(8):4014-23. doi: 10.4049/jimmunol.1200798. Epub 2012 Sep 12.

Supplemental Content

Support Center